miR-141 Contributes to Fetal Growth Restriction by Regulating PLAG1 Expression

Qiuqin Tang1,2,*, Wei Wu1,3,4,*, Xia Xu1,2, Lu Huang1, Qiong Gao2, Huijuan Chen1, Hong Sun5, Yankai Xia3,4, Jiahao Sha3, Xinru Wang3,4, Daozhen Chen6, Qian Xu1

1 Department of Obstetrics, Wuxi Hospital for Maternal and Child Health Care, Wuxi, China, 2 First Clinical Medical College of Nanjing Medical University, Nanjing Medical University, Nanjing, China, 3 State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, China, 4 Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China, 5 Department of Microbial and Molecular Systems, KU Leuven, Leuven, Belgium, 6 Department of Laboratory, Wuxi Hospital for Maternal and Child Health Care, Wuxi, China

Abstract

Background: Fetal growth restriction (FGR) is an important but poorly understood condition of pregnancy, which results in significant fetal, neonatal and long-term morbidity and mortality. Novel research has suggested that altered miRNA expression in the plasma and placenta is associated with adverse pregnancy. We hypothesized that aberrant expression of microRNA-141 (miR-141) in the placenta is associated with FGR. Additionally, expression levels of predicted target genes of miR-141 were also analyzed in placental tissues of FGR and normal controls.

Methodology/Principal Findings: Using quantitative real time PCR, we analyzed the expression level of miR-141 and its target genes in placentas of FGR pregnancies (n = 21) and normal controls (n = 34). Western blot was used to detect the protein expression level of the target genes of miR-141. MiR-141 showed significant up regulation in FGR and significant down regulation of its targets, i.e. E2F transcription factor 3 (E2F3) protein, pleiomorphic adenoma gene 1 (PLAG1) mRNA and protein. Moreover, a positive correlation was found between PLAG1 and insulin-like growth factor 2 (IGF2) expression levels (Spearman r = 0.56, p<0.0001). MiR-141 yields an AUC of 0.83 with 88.5% sensitivity and 71.7% specificity for separating FGR from normal controls. This study indicates that miR-141 may be diagnostically important in FGR.

Conclusions/Significance: Our results indicate that aberrant high expression level of miR-141 might play important roles in the pathogenesis of FGR by suppressing E2F3 and PLAG1. We propose that miR-141 may participate in a miR-141-PLAG1-IGF2 network relating to FGR development. These findings may provide new targets via miR-141 in diagnosis and therapy of FGR in the future.

Introduction

Fetal growth restriction (FGR), also known as intrauterine growth restriction (IUGR), is defined as the inability of a fetus to maintain expected growth, with estimated fetal weight or actual birth weight below the 10th percentile for gestational age [1]. It is a relatively common, pleiotropic complication of pregnancy, affecting approximately 5–10% of newborns [2], and it is the second primary cause of perinatal mortality. FGR is associated with significantly increased perinatal morbidity and mortality, and is also a major determinant of cardiovascular disease and glucose intolerance in adult life [3]. Several factors have been identified to be involved in pathogenesis of FGR, including infectious [4], chromosomal alterations [5] or genetic syndromes [6,7], drug abuse or chemical substances [8], abnormalities of the placenta [9], as well as immunological and anatomical factors [10]. In most cases, however, incomplete placentopoeisis (placental formation) is the cause for the insufficient supply of nutrients and oxygen to the fetus that subsequently causes the deceleration of its growth.

The placenta is of critical importance to ensure the proper growth and development of the fetus while in utero. It is involved in providing the fetus with nutrients and also is involved in waste and gas exchange. The molecular machinery underlying placental development and function is complex, and comprises numerous interconnected regulatory pathways. Mutations of proteins involved in these molecular networks derail murine placental morphogenesis and commonly lead to embryonic lethality or abnormal fetal growth [11].

MicroRNAs (miRNA) are small non-coding RNAs that regulate gene expression through mRNA degradation and translational repression [12]. It has been reported that one third of human genes are regulated by miRNAs [13]; each miRNA can interact with many miRNAs, and conversely each miRNA can be regulated by multiple miRNAs. In recent years, miRNAs have been shown...
to play a fundamental role in a variety of physiological and pathological processes in human and animals. They can participate to control several biological processes including cell growth, apoptosis, development, metabolism, stress adaptation, hormone signaling and differentiation [12,14,15].

Currently, most of the miRNA-related studies compare cancer cells versus normal cells, but the analysis of miRNAs in the control of physiological processes including pregnancy is just incipient. Aberrant miRNA expression has been linked to discrete pathologic processes [16]. Current reports have demonstrated specific patterns of miRNAs regulating changes in uterine gene expression [17] or miRNAs that are specifically expressed in embryonic stem cells and whose expression is altered during embryonic development [18]. As the placenta plays a pivotal role in governing fetal development, it is not surprising that placenta expresses numerous types of miRNAs. Whereas many of these miRNAs are ubiquitously expressed, certain miRNA species are very unique to the placenta. Recent reports on miRNA expression profiles in placenta from preeclampsia pregnancies versus normal pregnancies suggested the involvement of some miRNAs in the pathogenesis of preeclampsia [19]. However, the function of miRNAs in FGR is poorly understood. We focused on miR-141 that was previously published to correlate with tumor grade, to be implicated in pregnancy. MiR-141, belonging to the miR-200 cluster, is found up-regulated in nasopharyngeal and ovarian carcinomas in comparison with normal tissues and correlates with poor prognosis [20,21]. As biological marker, levels of miR-141 are increased in plasma from pregnant women [22]. Therefore, in our present study, we analyzed the expression level of miR-141 in patients with FGR and investigated its potential molecular mechanisms.

Materials and Methods

Sample Collection

This study was approved by the Institutional Ethics Committee of Nanjing Medical University. Written informed consent was obtained from each participant. The placental tissue samples, delivered at 37–42 weeks, were collected from 21 pregnant women complicated with FGR undergoing cesarean section in the Department of Obstetrics and Gynecology of Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, from January 2011 through December 2011. Placental tissues from 34 normal pregnancies with gestational age matched groups also undergoing selective cesarean section were collected as controls. All patients had normal platelet counts, normal functioning livers and kidneys, and normal blood pressure. All placental samples were frozen within a half hour after delivery and frozen in liquid nitrogen and stored at –70°C until extraction of RNA and protein.

RNA Extraction and Quantitative Real-time PCR

TRizol reagent (Invitrogen Technologies Co, USA) was used to isolate the total RNA, all the procedure were performed under the protocol described by the manufacturer. The expression level of miR-141 was quantified with TaqMan RT-PCR assays (Applied Biosystems). RT-PCR reactions were carried out using the manufacturer’s recommendation. In brief, 1 μg of total RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) with miR-141 specific RT-primer (Applied Biosystems). qPCR was performed triplicate in a volume of 10 μl with 384-well plates on ABI Prism 7900HT (Applied Biosystems) with a standard absolute quantification thermal cycling program and using the SDS 2.3 software to determine the cycle threshold (Ct). Cycling conditions were as follows: incubation at 50°C for 2 min, denaturation at 95°C for 10 min, followed by 40 cycles of denaturation for 15 s at 95°C, annealing and extension for 1 min at 60°C. After the reactions, the Ct data were determined using default threshold settings and the mean Ct was determined from the triplicate PCRs. U6 snRNA (RNU6B, Applied Biosystems) served as an endogenous control. The amount of miR-141 was normalized relative to the amount of RNU6B (ΔΔCt = ΔCt miR-141-ΔCt U6).

A total of 500 ng of total RNAs from placental tissue samples were used for reverse transcription (Takara, Tokyo, Japan) under 37°C for 15 min and 95°C for 30 s. The PCR reaction was performed using the SYBR Green Master Mix (Takara) in ABI Prism 7900HT (Applied Biosystems, Foster City, CA) with the gene-specific primers. All primer sequences are shown in Table 1. PCR was performed for 5 seconds at 95°C and for 30 seconds at 60°C for 40 cycles. At the end of the PCR cycles, melting curve analyses were performed to validate the specificity of the expected PCR product. Each assay was performed in three independent technical replicates. The results were normalized for the level of GAPDH. Relative expression of target genes were calculated using the equation 2^(-ΔΔCt) in which ΔΔCt = ΔCt (target gene) - ΔCt GAPDH.

Western Blot

Protein extracts were prepared from placental tissues using RIPA buffer containing protease inhibitors (Complete, ULTRA, Mini, EDTA-free, EASYpack Roche). After extracting, the protein concentration was detected by BCA method. Equal amount of proteins (100 μg) were separated by 12.3% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane. Membrane was blocked using 5% skimmed milk and incubated with respective antibodies. Equal amount of protein was confirmed using GAPDH antibody. The primary and secondary antibodies are listed in Table S1. Integrated density values were then calculated using AlphaImager 3400 (Alpha InnoTech, San Leandro, CA, USA). These values were then normalized to GAPDH level.

Table 1. Primers used for reverse transcription and quantitative real-time PCR in the placenta.

| mRNA | Primer | Sequence |
|------|--------|----------|
| E2F3 | Forward | 5’-AGAAAGGGCTATCATAGTACT-3’ |
| Reverse | 3’-TGCAGCTGATGACGCT-3’ |
| PLAG1 | Forward | 5’-ATACACCTCATAACACGG-3’ |
| Reverse | 3’-AGCCCTGATTGATTGTCTGCC-3’ |
| TGF2 | Forward | 5’-CAGCAGACTGATGATGAACCA-3’ |
| Reverse | 3’-CTTGCCGGTGAGATAGCT-3’ |
| CUL3 | Forward | 5’-AATGTCGACGAGATGTTA-3’ |
| Reverse | 3’-TTGTTCTCCGGTTGATT-3’ |
| ZEB2 | Forward | 5’-CAAGGGGCGCACAACAGGC-3’ |
| Reverse | 3’-GGTGTGGAATACCCTGATCC-3’ |
| IGF2 | Forward | 5’-TTTGGCTCTCCCTCCTCCA-3’ |
| Reverse | 3’-CAAGAGCTCTGCTGGAAACAT-3’ |
| GAPDH | Forward | 5’-GGAGGGAGATGCTCCAAAT-3’ |
| Reverse | 3’-GGTCTGGTCACTATGCTCAGG-3’ |

doi:10.1371/journal.pone.0058737.t001
miRNA Target Predictions and Pathway Analysis
Potential target genes of miR-141 were identified using the DIANA LAB [http://diana.cslab.ece.ntua.gr/], PicTar [http://pictar.bio.nyu.edu] and TargetScan human 6.0 [http://www.targetscan.org/vert_60/] search engines. Putative target genes were selected for further validation if they were predicted by at least 2 databases mentioned above. The Database for Annotation, Visualization and Integrated Screening (DAVID) [http://david.abcc.ncifcrf.gov] was applied to provide the functional annotation according to the KEGG database [http://www.genome.jp/kegg/].

Statistical Analysis
The data were presented as mean ± SD. We used the method of 2−ΔΔCt to analyze the result of RT-PCR in all of our experiments. Statistical analysis of gene expression was performed by Mann-Whitney test. To investigate the correlation between miR-141 expression and three target genes, we calculated Spearman correlations for their expression. All statistical analyses were carried out using Stata (Version 9.2, StataCorp, LP), and p≤0.05 was considered to be significant.

Results
Characteristics of the Sample Population
Fifty five human placental samples were analyzed for the expression of miR-141 and its target genes. The mean (SD) age of FGR and normal controls were 26.20 (3.49) and 27.91 (4.24), respectively. No significant difference was observed between FGR subjects and controls with regard to the age (p=0.127). The demographics of the sample population are given in Table 2.

miR-141 Expression in FGR and Normal Placental Tissues
To determine whether miR-141 expression is associated with FGR, we examined the expression level of miR-141 in FGR placental tissues compared with normal placental tissues using quantitative real-time PCR. The data showed that the expression level of miR-141 in FGR placenta is almost 3.4-fold higher in comparison to the control placenta (Figure 1; p=0.0036).

Expression Levels of miR-141 Target Genes in FGR and Normal Placental Tissues
To explore the potential mechanism by which miR-141 executes its function in FGR, we first applied three bioinformatics algorithms (DIANA LAB, PicTar and TargetScan) to identify its potential target genes. Six possible pathways were identified with not less than 10 predicted target genes in each pathway (Figure 2A). As presented in Table S2, four possible pathways were listed with p<0.001 (Figure 2B). They were Pathways in cancer, Chronic myeloid leukemia pathway, Wnt signaling pathway, and MAPK signaling pathway. Finally, we identified five potential targeted genes, i.e. E2F transcription factor 3 (E2F3), pleiomorphic adenoma gene 1 (PLAG1), transforming growth factor, beta 2 (TGFB2), cullin 3 (CUL3) and zinc finger E-box binding homeobox 2 (ZEB2) for further validation, using at least two of these algorithms. Among the five potential targeted genes, the mRNA expression level of PLAG1 was significantly decreased in patients with FGR compared with controls (p=0.0076) (Figure 1). However, no significant difference was observed in the expression levels of E2F3 and TGFB2 between FGR patients and normal controls (Figure 1). The expression of CUL3 and ZEB2 could not be detected in placental tissue.

The Relationship between Expression Level of mir-141 and its Target Genes in FGR
As we found that the expression level of PLAG1 was pronouncedly inhibited in FGR placental tissues compared with normal tissues (Figure 1). We speculated that the reduced PLAG1 expression in FGR could be a result of the elevated expression level of miR-141. Therefore, spearman correlation analysis was applied to compare the relative expression levels of miR-141 and PLAG1 in these human placental specimens. There was an inverse correlation between expression of miR-141 and PLAG1 (Spearman r=-0.20; p=0.13), though not reach statistical significance (Figure S1). The up regulation of miR-141 in FGR suppresses the mRNA expression level of PLAG1, which may in turns contribute to FGR. Additionally, previous studies have shown that PLAG1 may up regulate the expression of insulin-like growth factor 2 (IGF2), which has been shown to be critical for early human placental development and prenatal growth [23,24,25]. We analyses the correlation between expression level of PLAG1 and IGF2 in placental tissues of FGR and controls. A statistically significant positive correlation was found between expression of PLAG1 and IGF2 (Spearman r=0.56, p<0.0001) (Figure 3).

Protein Expression Levels of miR-141 Target Genes in FGR and Normal Placental Tissues
To further confirm the expression patterns of protein of miR-141 target genes, Western blot was used to measure the relative expression levels. The protein expression levels of E2F3 and PLAG1 in placental tissues were decreased in patients with FGR compared with normal controls (Figure 4). Similar as the mRNA expression levels, no significant change of protein level of TGFβ2 was found between the two groups.

Receiver Operating Characteristic (ROC) Curves of FGR Prediction with miR-141 Expression
By using the 95% reference interval of miR-141 expression value as risk scores, we constructed the ROC curves and calculated the Area Under the ROC Curve (AUC) to assess the
sensitivity and specificity for prediction. As depicted in Figure 5, miR-141 could serve as a potential biomarker to distinguish between FGR and normal controls with AUC of 0.839 and the sensitivity of 88.5% and specificity 71.7% (Figure 5).

Discussion

Recent reports have quantitatively analyzed the expression of up to 820 miRNAs in placental tissue samples collected in the first or third trimester. Interestingly, the concentration of pregnancy-
associated miRNAs increased throughout pregnancy and was altered in placentas from pregnancies with preeclampsia or preterm labor [26,27]. These results suggest miRNAs as potential serum markers for the normal function of the placenta. However, little is known about the miRNAs expression levels in placental tissue of FGR.

We provide the first evidence that the involvement of miR-141 in the pathology of FGR disease. MiR-141, belonging to the miR-200 cluster, is found to correlate with tumor grade, to be implicated in pregnancy. Chim et al. [28] suggested that several placental miRNAs (miR-141, miR-149, miR-299-5p, and miR-135b) were highly expressed in maternal plasma during pregnancy and noted that such expression patterns may serve as clinical biomarkers for pregnancy monitoring. However, they did not find any significant differences between FGR patients and controls with relative small sample size. In our present study, we demonstrated that FGR patients have higher expression level of miR-141 compared with normal controls. Furthermore, we analyzed five predicted miR-141 target genes expression and found that mRNA expression of PLAG1 was significantly decreased and the protein expression was also decreased. The protein expression of PLAG1 was consistent with the pattern observed at the mRNA level, indicating that miR-141 repress PLAG1 at both transcriptional and post-transcriptional level. However, the expression of E2F3 was only repressed by miR-141 particularly at the post-transcriptional level.

The E2F transcription factors have emerged as critical apoptotic effectors. The E2F family is essential for extra-embryonic cell proliferation, placental development, and fetal viability [29]. The E2F family member E2F3 protein contributes to control of proliferation in Rb mutant embryos in a tissue-specific manner, and plays a major role in the placenta and nervous system [30]. E2F3 is highly expressed in adult human tissues and is required for the appropriate development of placental tissues [31]. Additionally, the Plag1 proto-oncogene encodes a transcription factor and is implicated in human tumorigenesis via ectopic overexpression [32]. PLAG1 is located on human chromosome 8q12 whose oncogenic activation is a crucial event in the formation of various human tumors, including pleomorphic adenomas of the salivary glands [33], lipoblastoma [34], and hepatoblastomas [35]. PLAG1 is expressed mainly during embryonic development and is highly expressed in placenta [36]. Hensen et al. [32] found that targeted disruption of the murine Plag1 could cause growth retardation. In recent microarray analyses, genes were identified that are consistently induced or repressed by PLAG1, and these were classified into various functional categories. Among the classes of up-regulated PLAG1 targets, the one encoding growth factors was the largest and included the genes for IGF2, cytokine-like factor 1 (CLF1), bone-derived growth factor (BPGF1), choriongonadotropin beta chain (CGB), vascular endothelial growth factor (VEGF) and placental growth factor (PGF) [37]. In the present study, we also found that the expression level of PLAG1 was strongly positive correlated with the expression level of IGF2 in placental tissues of FGR and normal controls. These results was also consistence with previous report that the IGF2 mRNA level was significantly decreased in the
placental tissue from the FGR pregnancies [38]. Thus, we propose that miR-141 may participate in a miR-141-PLAG1-IGF2 network relating to FGR development.

Using the KEGG database we searched for pathways where the miR-141 target genes function in order to gain insight into the processes that could be affected by the dysregulated miR-141. The target genes of miR-141 were involved in several important signaling pathways, i.e. MAPK signaling pathway and Wnt signaling pathway. MAPK signaling pathway is implicated in regulating cell growth and differentiation [39]. Decreased MAPK signaling can contribute to defective placental development [40]. Mutation in this signaling cascade lead to defects in the placental labyrinthine region [41]. Additionally, Wnt signaling has been implicated in the regulation of cell proliferation, apoptosis and cell fate [42]. This pathway also played a critical role in both initiating and patterning of the anterior-posterior axis, which precedes gastrulation during mouse embryonic development. Aberrant expression of miR-141 might inactivate these two important pathways, consequently affecting placental development and fetal growth. Further study of MAPK and Wnt pathway may have implications for understanding the pathogenesis of FGR.

Downstream effects of miRNA on post-transcriptional gene regulation remain more challenging and require use of bioinformatics approaches to first predict mRNA targets of specific miRNA and then confirm the effects of over- or under-expression of miRNA on that particular target. Due to the miRNAs’ ultimate role in controlling protein translation, true confirmation of targets requires examination of the proteins of interest using specific antibodies, or through in-vitro approaches coupling targeted miRNA binding regions to reporter constructs. The understanding of miRNAs’ role in the human placenta is in its infancy but due to the known critical role of miRNA in human development, it is certainly an attractive and exciting field of study.

Our study has several limitations. The most important limitation is the size of the population studied. The sample size of our present study was relatively small. Future studies with larger sample size are needed to validate this association. Secondly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual data were available, which would allow for the adjustment by other co-variants including age, body mass index, smoking status, drinking status, and other lifestyle factors. Thirdly, only one miRNAs were involved in our study, while more miRNAs should be evaluated in the future, for instance identifying the miRNAs expression profiling using microarray assay.

Our data are the first to indicate that miR-141 was significantly upregulated in placental tissues of FGR compared with normal controls. In particular, we have demonstrated that the significantly increased miR-141 could serve as adjunct biomarkers for the diagnosis of FGR. Additionally, we propose the effect of up-regulated miR-141 contribute to FGR may through down regulation of E2F3 expression at post-transcriptional level and PLAG1 expression at both transcriptional and post-transcriptional level. These results provide novel information regarding the molecular mechanism of FGR and the clinical value of miR-141 pertinent to FGR. Further in-depth studies are required to unravel the functional significance of miR-141 in molding placental robustness, which must constantly adapt to altered maternal physiologic status to sustain optimal support to the developing embryo.

**Supporting Information**

**Figure S1** The correlation between expression level of E2F3 (A), PLAG1 (B), TGFβ2 (C) and miR-141 expression levels in placentas. The correlation was calculated by Spearman correlation analysis. (TIF)

**Table S1** The primary and secondary antibodies of miR-141 target genes and GAPDH were used in Western blot. (DOC)
Table S2  Pathways probably regulated by miR-141 in FGR. (DOC)

Acknowledgments

We thank Yan Zhu, Rong Lu for collection of placental samples. We thank all the sample donors who made this work possible.

References

1. Nardozza LM, Araujo Junior E, Barbosa MM, Caetano AC, Lee DJ, et al. (2012) Fetal growth restriction: current knowledge to the general Obs/Gyn. Arch Gynec Obstet 2016:1–13.
2. Froen JF, Gardosi J, Thrumann A, Francis A, Stray-Pedersen B (2004) Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand 83: 801–807.
3. Barker DJ, Gluckman P, Phillips DI, Tilling K, Winter PD, et al. (1993) Fetal nutrition and cardiovascular disease in adult life. Lancet 341: 938–941.
4. Neerhof MG (1995) Causes of intrauterine growth restriction. Clin Perinatol 22: 375–385.
5. Lin CC, Santolaya-Forgas J (1998) Current concepts of fetal growth restriction: part I. Causes, classification, and pathophysiology. Obstet Gynecol 92: 1044–1053.
6. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, et al. (2003) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 100: 10513–10518.
7. Davis BN, Hata A (2009) Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. Cell Commn Signal 7: 18.
8. Klooosterman W, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 141–145.
9. Maccani MA, Marit CJ (2009) Epigenetics in the placenta. Am J Reprod Immunol 60: 1–7.
10. Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23: 493.
11. Guido M, Meiri E, Yogev Y, Benjamin S, Lebanony D, et al. (2008) Serum Smad interacting protein 1 (SIP1) and inhibits migration and invasion of hepatoblastoma. Cancer Res 68: 1–7.
12. Miura K, Miura S, Yamakoa K, Togashi K, Akiyama A, Koshibu A, et al. (2010) Identification of pregnancy-associated microRNAs in maternal plasma. Clin Chim Acta 411: 1127–1131.
13. Feng J, Tian M, Shi Y, Shi Y, Shi Y, et al. (2008) Identification of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Clin Chim Acta 411: 726–732.
14. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
15. Zhang H, Liu Y, Li C, Li Y, Li Y, et al. (2009) MicroRNA-141 regulates hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Clin Chim Acta 411: 726–732.
16. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
17. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
18. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
19. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
20. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
21. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
22. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
23. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
24. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
25. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
26. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
27. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
28. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
29. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
30. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
31. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
32. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.
33. Mitchell PS, Zhang PL, Wiseman SM, Birditt S, Leinster SG, et al. (2008) MicroRNA: a new player in the regulation of gene expression. Mol Cell 30: 252–255.